Keyphrases
Overall Survival
100%
Treatment Regimen
100%
Phase II Trial
100%
Gynecologic Oncology Group
100%
Advanced Ovarian Cancer
100%
Platinum-based Treatment
100%
Progression-free Survival
75%
Carboplatin
75%
Paclitaxel
75%
Cytotoxic Agents
50%
Hazard Ratio
25%
Patient-completed
25%
Improved Outcomes
25%
Gemcitabine
25%
Survival Analysis
25%
Event-triggered
25%
Type I Error
25%
Prognostic Factors
25%
Advanced Stage
25%
Well-balancing
25%
Interim Analysis
25%
Topotecan
25%
Platinum-based Chemotherapy
25%
Residual Tumor
25%
Pairwise Comparison
25%
Coordinating Center
25%
Demographic Factors
25%
Primary Peritoneal Cancer
25%
Limited Form
25%
New Intervention
25%
Residual Disease
25%
Accruals
25%
Epithelial Ovarian Carcinoma
25%
Pegylated Liposomal Doxorubicin
25%
Maximum Diameter
25%
Multi-arm
25%
Optimal Cytoreduction
25%
Single Reference
25%
Suboptimal Cytoreduction
25%
Interval Cytoreduction
25%
Dual-stage
25%
Medicine and Dentistry
Arm
100%
Ovarian Cancer
100%
Female Genital Tract Cancer
100%
Phase III Trials
100%
Overall Survival
80%
Progression Free Survival
60%
Carboplatin
60%
Paclitaxel
60%
Krukenberg Tumor
40%
Cytotoxic Agent
40%
Neoplasm
20%
Hazard Ratio
20%
Tail
20%
Topotecan
20%
Prognostic Factor
20%
Minimal Residual Disease
20%
Doxorubicin
20%
Survival Analysis
20%
Gemcitabine
20%
Primary Peritoneal Carcinoma
20%
Interim Analysis
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Ovary Cancer
100%
Female Genital Tract Cancer
100%
Phase III Trials
100%
Progression Free Survival
75%
Paclitaxel
75%
Carboplatin
75%
Ovary Carcinoma
50%
Cytotoxic Agent
50%
Neoplasm
25%
Chemotherapy
25%
Carcinoma
25%
Doxorubicin
25%
Minimal Residual Disease
25%
Gemcitabine
25%
Topotecan
25%
Diseases
25%